The mice were injected intravenously, and the long-term anti-tumor immunity results showed that after 30 d of treatment, the proportion of T cells (CD45+CD3+CD44+) in lymph nodes of mice was about six times higher than that of tumor-bearing mice and healthy mice after 1 d of treatment. Here, PTPRC is linked to neoplasm.